Tirzepatide, semaglutide, peptide adjuncts, hormone optimization, and a lean-mass-preservation architecture — designed and monitored by Dr. Joshua Hare, DO. The drug is one tool. The system is the result.
Book a Consultation How the Program WorksThe current generation of GLP-1 / GIP medications produces 14–22% mean weight loss in Phase 3 trials. The next generation — retatrutide — is reading out at 28.7%. These are the most effective metabolic interventions ever made widely available.
And yet the real-world failure mode of weight-loss medication is not that the drugs don't work. It's that they're prescribed without an architecture beneath them — without lab work, without hormone optimization, without lean-mass preservation, without an exit plan. Two-thirds of weight is regained within twelve months of stopping unless that architecture is built.
The Limitless weight loss program is the architecture. The medication is one component of it.
Whether the patient is on tirzepatide, semaglutide, or no drug at all, these four pillars are non-negotiable. Drugs amplify what's underneath them. Without the pillars, drugs lose their leverage.
Tirzepatide for most. Semaglutide when CV protection is the priority. Drug choice driven by labs, comorbidities, and goals — not whichever drug the loudest voice is recommending.
Testosterone, thyroid, cortisol screened and treated. Untreated hypogonadism caps weight loss in men. Subclinical hypothyroidism slows everything in women.
Protein 1.6–2.2 g/kg. Resistance training 3×/week minimum. Creatine 5g daily. Without this, 25–35% of GLP-1 weight loss is lean tissue — unacceptable for longevity.
Discontinuation strategy designed at intake — taper protocols, maintenance dosing, lifestyle anchors. We treat GLP-1s as ongoing therapy unless you choose otherwise.
Three drugs dominate the conversation in 2026. We prescribe two of them today, and we'll add the third when it launches. Here is the honest breakdown.
Mounjaro (T2D) and Zepbound (obesity, OSA). Dual GLP-1 + GIP agonist. The current standard of care for most weight-loss patients. SURMOUNT-5 confirmed superiority over semaglutide head-to-head. Also approved for obstructive sleep apnea.
Ozempic (T2D) and Wegovy (obesity). Single GLP-1 agonist. Prescribed when cardiovascular protection is the priority — the SELECT trial demonstrated 20% reduction in major adverse cardiovascular events in patients with established CV disease.
Eli Lilly's triple agonist (GLP-1 + GIP + glucagon). TRIUMPH-4 produced the highest weight-loss figure ever in a Phase 3 obesity trial. Investigational as of May 2026; not legally compoundable. We do not source from gray markets. When approved, it joins the formulary.
For the full landscape — including CagriSema, orforglipron, and survodutide — read our 2026 GLP-1 landscape primer.
The peptide formulary is what differentiates a Limitless weight-loss program from a typical telehealth GLP-1 prescription. These are the most-used adjuncts:
The 2026 tesamorelin pooled meta-analysis — −27.7 cm² VAT and +1.42 kg lean mass — is precisely the profile we layer onto GLP-1 therapy when scale weight moves but visceral fat does not, and when lean-mass preservation matters more than scale numbers. Tesamorelin — what the 2026 meta-analysis actually shows →
60-minute new-patient visit with Dr. Hare. History, goals, prior labs, contraindications. We map your protocol — not a template.
CMP, A1c, fasting insulin, lipids, hormones (sex + thyroid + cortisol), hs-CRP, vitamin D, B12. Body composition (DEXA or InBody).
Drug selection, hormone correction, peptide adjuncts, training and protein architecture, supplement plan. Documented in the portal.
4-week tolerability check. 12-week labs and dose decision. 24-week full review. Adjust on data, not vibes.
One year out, we make the maintenance decision together — taper, hold, or continue — based on results, comorbidities, and goals. The program is built to graduate you, not to keep you on therapy forever.
FDA-labeled criteria for the obesity indication of Wegovy and Zepbound:
Tirzepatide is also FDA-approved for obstructive sleep apnea in adults with obesity. Semaglutide is approved for cardiovascular event reduction in patients with established CV disease.
We deliberately decline to prescribe for patients with personal/family history of medullary thyroid carcinoma or MEN-2, active pancreatitis, severe gastroparesis, active eating disorders, pregnancy or planned pregnancy, BMI < 25 with no metabolic disease, or patients seeking short-term cosmetic loss without commitment to ongoing therapy and lifestyle architecture.
For the full candidate-selection framework — including special populations, screening labs, and the patients we ask to start somewhere else — read our "Are You a Candidate?" guide.
Dr. Hare's deep-dive series on the GLP-1 / GIP / glucagon landscape, anchored to the latest Phase 3 data. Educational, not promotional.
Phase 3 TRIUMPH-4 produced 28.7% mean weight loss. Mechanism, FDA timeline, and what it changes about how we approach weight loss.
SURMOUNT-5 (NEJM 2025) — the only randomized head-to-head trial. 20.2% vs. 13.7%. How to choose between Zepbound and Wegovy.
Every drug, every generation. Semaglutide to retatrutide, plus orforglipron, CagriSema, survodutide.
Tesamorelin, MOTS-c, hormone optimization, lean-mass protection. The toolkit drugs alone cannot replace.
BMI thresholds, contraindications, screening labs, monitoring. The patients we deliberately decline to prescribe for.
86% liver fat reduction, 14 mmHg BP drops, 2.0% A1c reduction, plus emerging cognitive and addiction signals. The secondary endpoint story.
The integrated regimen Dr. Hare runs himself — sleep, training, peptides, hormones, labs. Not medical advice. A working example.
The fastest path from "I'm thinking about this" to "I have a plan." 60-minute new-patient visit with Dr. Hare. In-person in Dalton or telehealth across Georgia.
Limitless launches May 2026. Founding members lock pricing for 24 months and receive a complimentary NAD+ loading credit. Twenty-five spots remaining.
Book a Consultation Founding Membership